Actinogen Medical Limited (ATGGF) Fair Value & Analysis
Healthcare · US · Market cap $2.9M
Actinogen Medical Limited
ATGGF · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 26 days ago
Price vs Fair Value (12 months)
12‑month range $0.0008 – $0.0400 · the $0.0008 price screens above the $0.0007 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Actinogen Medical Limited (ATGGF) currently trades at $0.0008, while our model-based Fair Value estimate is $0.0007, implying the stock looks roughly 15.2% overvalued today. We read business quality at 21/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $7.4M. Revenue declined 39.2% year over year. The balance sheet holds a net cash position of $13.2M. Fundamentals as of Jun 26, 2026
For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -15%, ATGGF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Actinogen Medical Limited reported revenue of $5.5M in FY2025 versus $2.0M in FY2021, a compound +29.0%/yr. Reported net income was −$14.7M in FY2025.
Is ATGGF fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.46 | R$21.38 | -27% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,704 | kr 209.21 | -88% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Actinogen Medical Limited (ATGGF) undervalued?
What is the fair value of ATGGF?
What is the quality score of ATGGF?
What is the revenue of Actinogen Medical Limited (ATGGF)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Actinogen Medical Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.